Targeting vasoactive peptides for managing calcific aortic valve disease

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Biochemistry

Background:

• Calcific aortic valve disease (CAVD) prevalence increases with age, affecting up to 2.8% of individuals over 75.
• Aortic sclerosis, a milder form of CAVD, elevates myocardial infarction and cardiovascular death risk by 50%.
• Current pharmacological treatments, including statins and renin-angiotensin system (RAS) blockers, have failed to slow CAVD progression.

Purpose of the Study:

• To review the role of vasoactive factors in CAVD pathogenesis.
• To identify novel pharmacological targets for treating aortic valve calcification.
• To explore the potential of circulating vasoactive factors as diagnostic markers for CAVD.

Main Methods:

• Review of existing literature on vasoactive systems and CAVD.
• Analysis of studies investigating endothelin, apelin, and RAS in aortic stenosis (AS).
• Discussion of therapeutic implications of targeting these pathways.

Main Results:

• Vasoactive factors, including endothelin and apelin systems, are implicated in AS development.
• The renin-angiotensin system (RAS) and endothelin system are prominent targets for CAVD intervention.
• Circulating vasoactive factors may serve as diagnostic indicators for CAVD.

Conclusions:

• Vasoactive factors are crucial in the pathogenesis and progression of CAVD.
• Targeting endothelin and RAS pathways presents promising therapeutic strategies for CAVD.
• Further research into circulating vasoactive factors could lead to improved diagnostic tools for CAVD.